Lymphomas | Clinical

CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL

April 12, 2021

Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.

Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHL

April 10, 2021

Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Novel Combinations Excite the R/R Hodgkin Lymphoma Treatment Landscape

April 08, 2021

While the treatment of relapsed or refractory Hodgkin lymphoma has seen novel approaches in recent years improving outcomes for many patients, high-risk patients develop progressive disease and have limited treatment options.

Toxicities From Tafasitamab Monotherapy Are Less Severe After Discontinuing Lenalidomide in R/R DLBCL

April 04, 2021

The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.